Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated
NCT02870907Phase 2Active, not recruiting
- Sponsor
- Institut Curie
- Start
- Mar 2010
- Primary completion
- Mar 2031
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of etoposide, carboplatin, vincristine sulfate liposome injection, cyclophosphamide, thiotepa in retinoblastoma (Rb), sponsored by Institut Curie. Started Mar 2010; status: active, not recruiting.
02
Drugs
etoposidecarboplatinvincristine sulfate liposome injectioncyclophosphamidethiotepa
03
Conditions
retinoblastoma (Rb)
Beyond the preview
Go deeper on NCT02870907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02870907.